Hepatitis B Surface Antigens (HBsAg)

Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.

Also Known As:

Networked: 10291 relevant articles (395 outcomes, 1036 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kao, Jia-Horng: 43 articles (11/2015 - 10/2002)
2.	Chen, Ding-Shinn: 38 articles (08/2015 - 06/2002)
3.	Chen, Pei-Jer: 35 articles (05/2015 - 07/2002)
4.	Lu, Sheng-Nan: 33 articles (11/2015 - 01/2002)
5.	Liaw, Yun-Fan: 30 articles (08/2015 - 06/2002)
6.	Janssen, Harry L A: 28 articles (01/2016 - 02/2006)
7.	Lai, Ching-Lung: 27 articles (09/2015 - 01/2003)
8.	Liu, Chun-Jen: 27 articles (01/2015 - 10/2002)
9.	Tanaka, Yasuhito: 26 articles (09/2015 - 04/2005)
10.	Yuen, Man-Fung: 25 articles (09/2015 - 06/2004)

Related Diseases

1.	Infection 09/01/2015 - "Although genomic detection is considered the gold standard test on HBV infection identification, the HBsAg investigation is still the most frequent clinical laboratory request to diagnose HBV infection in activity. " 05/12/2015 - "Moreover, in most clinically studied samples, HDV infection is associated with a dramatically reduced HBV viral load, temporarily or permanently, while HBsAg resources are available for HDV packaging. " 02/01/2014 - "Endogenous HBV-CpG ODNs from the HBV genome induce IFN-α production so that nanoparticle-encapsulated HBV-CpG may act as an HBsAg vaccine adjuvant and may also represent a potent therapeutic agent for the treatment of chronic HBV infection." 01/01/1991 - "Moreover, pre-S(2)Ab appeared before HBsAb in 57.1% of our patients and was found in some patients before pre-S(1)Ag and HBsAg had cleared (42.8%), thus allowing complete viral clearance and acute HBV infection to be predicted earlier." 05/01/1990 - "These data show that the route of HBV infection rather than the sex appears to have a more important role in the rapid clearance of HBsAg."
2.	Hepatitis B 05/01/2010 - "In addition, the very large population of patients who have been exposed to the virus and have apparently cleared the virus as assessed by serological testing (HBsAg negative/hepatitis B core antibody [HBcAb] positive) may also be at risk of reactivation. " 01/01/2003 - "-B(Eng) had excellent protective efficacy against HBsAg carriage in healthy infants and children, and in neonates born to hepatitis B carrier mothers (protective efficacy of 95-99%). " 08/01/1994 - "The results show that long-term protection against HBsAg carriage of hepatitis B vaccination is very high and that a booster dose at school age does not significantly increase this protection." 12/01/1998 - "There was no significant difference in the donors' hepatitis B surface antibody titer before BMT for patients with or without serologic clearance of hepatitis B surface antigen (2255.2+/-4244.0 vs. 854.2+/-2306.7 mIU/mL; P=not significant). " 08/01/1990 - "High-anti-pre-S level in fulminant hepatitis B patients was assumed to be implicated in the fast clearance of HBsAg from circulation."
3.	Chronic Hepatitis B 06/01/2014 - "During the natural course of chronic hepatitis B, changes or absolute level of sAg less than certain level can predict spontaneous sero-clearance of HBsAg. " 08/01/2013 - "Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study." 01/01/2012 - "Among fifty-eight sera, ELISA showed fifty-five (94.8%) of the samples were positive for HBsAg and three (5.2%) negative results obtained while real-time PCR specified fifty-eight (100%) positive results in chronic hepatitis B patients. " 12/01/2010 - "  Specimens collected from 43 cases of chronic hepatitis B patients with positive results for both HBsAg and HBsAb tests were used as the experimental group; specimens collected from 43 cases randomly picked from all patients with chronic hepatitis B with a single positive result for HBsAg test were used as the control group. " 08/01/2009 - "Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B."
4.	Hepatitis 07/01/1985 - "Kinetics of synthesis of anti-pre-S antibody in the course of acute type hepatitis followed by elimination of HBsAg and recovery suggest the important role of this antibody in immunological neutralization and clearance of infective HBV particles. " 05/01/2007 - "In multivariate analysis, the probability of HBsAg seroclearance correlated positively with age at entry (P<0.0001) and sustained remission of hepatitis (P<0.0001) and marginally significantly with male sex (P=0.053). " 03/26/1999 - "Concerning the vaccination impact on HBV endemicity in Italy, we found a significant reduction of acute viral hepatitis incidence (4.2/100,000 in 1996 versus 19/100,000 in the '80s) and HBsAg carrier prevalence (0.9% in 1997 versus 3% in the '80s). " 01/01/1976 - "The results suggest that an unusually strong and rapid immune clearance of HBSAg may be involved in the pathogenesis of fulminant hepatitis." 05/30/1999 - "IFN therapy for chronic HBV hepatitis consisted of IFN 5 MU thrice weekly for 6 months, and resulted in 33% seroconversion and sustained remission with 14% HBsAg clearance. "
5.	Chronic Hepatitis (Chronic Active Hepatitis) 11/01/2013 - "When applying the grading of recommendation, assessment, development, and evaluation (GRADE) methodology, evidence from RCTs was considered of very low quality regarding the question of whether hepatitis B can be prevented for 15 years after successful primary vaccination (anti-HBs ≥ 10 IU/l) with a vaccine efficacy of 96 % against chronic hepatitis, 89 % against HBsAg positivity, and 73 % against isolated anti-HBc positivity. " 06/01/1981 - "These results would suggest the possibility of a spontaneous complete remission of HBsAg positive chronic active hepatitis in children but also raise doubts about the usefulness of immunosuppressive therapy in such patients." 01/01/1987 - "Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis." 02/01/1985 - "The efficacy of immunosuppressive treatment was evaluated in a group of 15 children (aged 2-10 years) affected by clinically asymptomatic, biochemically mild, HBSAg-positive, delta-antibody-negative, histologically moderate, chronic active hepatitis (CAH). " 04/01/1978 - "A study of lymphocyte cytotoxicity for rabbit hepatocyte cultures in 15 patients with untreated chronic active hepatitis showed positive results in all cases, both HBsAg positive and negative. "

Related Drugs and Biologics

1.	Hepatitis B Surface Antigens (HBsAg)
2.	Antigens
3.	Hepatitis B e Antigens
4.	DNA (Deoxyribonucleic Acid)
5.	Lamivudine (3TC)
6.	Surface Antigens (Surface Antigen)
7.	hepatitis B hyperimmune globulin
8.	Hepatitis B Vaccines (Hepatitis B Vaccine)
9.	Interferons
10.	Antibodies

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Transplants (Transplant)
3.	Aftercare (After-Treatment)
4.	Transplantation (Transplant Recipients)
5.	Blood Transfusion (Blood Transfusions)